-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA WITH PRIORITY REVIEW STATUS FOR SAVOLITINIB FOR THE TREATMENT OF GASTRIC CANCER PATIENTS WITH MET AMPLIFICATION

Reuters·12/30/2025 10:00:00

Please log in to view news